CAMBRIDGE, Mass., Jan. 7 /PRNewswire/ -- Biogen, Inc. (Nasdaq: BGEN) will
be presenting a company update at the JP Morgan H&Q Healthcare Conference in
San Francisco.
(Photo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
The presentation will be web cast live for investors at http://www.biogen.com
WHO: James C. Mullen, President and Chief Executive Officer of
Biogen, Inc.
WHEN: January 8, 2002 at 8:30 a.m. (PST)
WHERE: JP Morgan H&Q Healthcare Conference
Westin St. Francis Hotel
San Francisco, CA
CONTACT: Rob Jacobson, rob_jacobson@biogen.com, Biogen, Inc.
Biogen, Inc., winner of the U.S. National Medal of Technology, is a
biopharmaceutical company principally engaged in discovering and developing
drugs for human healthcare through genetic engineering. Headquartered in
Cambridge, MA, the Company's revenues are generated from international sales
of AVONEX for treatment of relapsing forms of multiple sclerosis, and from the
worldwide sales by licensees of a number of products, including alpha
interferon and hepatitis B vaccines and diagnostic products. (Please see full
prescribing information at http://www.avonex.com) Biogen's research and
development activities are focused on novel products to treat inflammatory and
autoimmune diseases, neurological diseases, cancer, fibrosis and congestive
heart failure. For copies of press releases and additional information about
the Company, please consult Biogen's Homepage on the World Wide Web at
http://www.biogen.com
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.biogen.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
CONTACT:
Rob Jacobson of Biogen, Inc.,
rob_jacobson@biogen.com
|
